March 1, 2012
Ruxolitinib in Myelofibrosis: Only for Some Patients
The first drug ever approved for myelofibrosis, ruxolitinib (Jakafi, Incyte/Novartis), is useful only in about 25% of patients with this disorder, according to Ayalew Tefferi, MD, from the division of hematology at the Mayo Clinic Rochester, Minnesota. Even then, it might not be the best option, he added. Dr. Tefferi was speaking to Medscape Medical […]
Tags: Ayalew Tefferi, myelofibrosis, New England Journal of Medicine, ruxolitinib